The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2017

Filed:

Jun. 08, 2015
Applicant:

Universite D'aix-marseille, Marseilles, FR;

Inventors:

Pierre Cau, Puyricard, FR;

Nicolas Levy, Marseilles, FR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 37/36 (2006.01); A61K 31/66 (2006.01); A61K 31/675 (2006.01); A61K 31/497 (2006.01); C07D 239/42 (2006.01); A61K 31/505 (2006.01); A61K 31/44 (2006.01); A61K 31/425 (2006.01); A61K 31/34 (2006.01); A61K 31/215 (2006.01); A61K 31/22 (2006.01); A61K 45/06 (2006.01); A61K 31/427 (2006.01); A61K 31/496 (2006.01); A61K 31/366 (2006.01); A61K 31/4025 (2006.01); A61K 31/665 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/215 (2013.01); A61K 31/22 (2013.01); A61K 45/06 (2013.01); A61K 31/366 (2013.01); A61K 31/4025 (2013.01); A61K 31/427 (2013.01); A61K 31/496 (2013.01); A61K 31/66 (2013.01); A61K 31/665 (2013.01);
Abstract

This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.


Find Patent Forward Citations

Loading…